1. A liquid crystal display comprising
two substrates on which alignment films for orienting liquid crystal in a predetermined direction are formed, the alignment films facing each other across a predetermined gap by a sealing material to bond the pair of substrates between which a liquid crystal layer is sandwiched, wherein
the sealing material contains a filler having a mean particle size of less than 0.5 \u03bcm and a maximum particle size of 1.5 \u03bcm or less,
the liquid crystal material used in the liquid crystal layer has a refractive index anisotropy at room temperature of 0.16 or more, and a cell mean gap is substantially 3 \u03bcm at a relative contrast ration of 1.
2. A liquid crystal display as set forth in claim 1, wherein the liquid crystal material used in the liquid crystal layer has a refractive index anisotropy at room temperature of 0.18 or more.
3. A liquid crystal display as set forth in claim 1, wherein the content of the filler contained in the sealing material is within a range of 15 to 40 wt %.
4. A liquid crystal display as set forth in claim 1, wherein a specific surface area of the filler contained in the sealing material is 30 m2g or less.
5. A liquid crystal display as set forth in claim 4, wherein the alignment film material is an inorganic alignment film.
6. A liquid crystal display as set form in claim 1, wherein the alignment film material is an inorganic alignment film.
7. The projection type display apparatus as set forth in claim 1, further comprising:
a light source, a condensing optical system for guiding the light emitted from the light source to said liquid crystal display device, and
a projection optical system for enlarging and projecting light modulated by the liquid crystal display device.
The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.
1. A solid font of the compound of formula (I)
having an XRPD pattern comprising at least one XRPD peak in the range of angles of diffraction 2Theta of 10.3\xb0 to 13.3\xb0, wherein the solid form is crystalline (1,1-dioxo-1\u03bb6-thiomorpholin-4-yl)-{6-3-(4-fluoro-phenyl)-5-methyl-isoxazol-4-ylmethoxy-pyridin-3-yl}-methanone in anhydrous polymorphic form C.
2. The compound of claim 1, comprising crystalline 1,1-dioxo-1\u03bb6-thiomorpholin-4-yl)-{6-3-(4-fluoro-phenyl)-5-methyl-isoxazol-4-ylmethoxy-pyridin-3-yl}-methasone in anhydrous polymorphic form C, having an XRPD diffraction pattern comprising XRPD peaks at angles of diffraction 2Theta of approximately 17.4\xb0, 23.4\xb0.
3. The compound of claim 1, having crystalline polymorphic form C, having the XRPD diffraction pattern of FIG. 3.
4. The compound of claim 1, comprising crystalline polymorphic form C, having the FTIR spectrum of FIG. 10.
5. The compound of claim 1, comprising crystalline polymorphic form C, having the Raman spectrum of FIG. 16.
6. The solid form of claim 1, having a purity of at least 90% (ww).
7. A high-shear process for preparing a solid form of a compound of formula (I)
having an XRPD pattern comprising at least one XRPD peak in the range of angles of diffraction 2Theta of 103\xb0 to 13.3\xb0 comprising:
a) injecting a solution of an educt solid form of compound (I) in a solvent into a high-shear mixer having a rotor-stator system comprising an antisolvent;
b) agitating the rotor-stator system of the high-shear mixer to form a suspension; and
c) physically separating the solid form from the suspension.
8. A pharmaceutical composition comprising a solid form of a compound of formula (I) the compound of formula (I)
having an XRPD pattern comprising at least one XRPD peak in the range of angles of diffraction 2Theta of 103\xb0 to 13.3\xb0
and a pharmaceutically acceptable excipient,
wherein the solid form is crystalline (1,1-dioxo-1\u03bb6-thiomorpholin-4-yl)-{6-3-(4-fluoro-phenyl)-5-methyl-isoxazol-4-ylmethoxy-pyridin-3-yl}-methanone in anhydrous polymorphic form C,
wherein the pharmaceutical composition is administered in an administrative form selected from tablets, powders, and capsules.